Yoshiya Horimoto

1.8k total citations
97 papers, 1.2k citations indexed

About

Yoshiya Horimoto is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yoshiya Horimoto has authored 97 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 32 papers in Cancer Research and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yoshiya Horimoto's work include Breast Cancer Treatment Studies (20 papers), Cancer Cells and Metastasis (18 papers) and Breast Lesions and Carcinomas (17 papers). Yoshiya Horimoto is often cited by papers focused on Breast Cancer Treatment Studies (20 papers), Cancer Cells and Metastasis (18 papers) and Breast Lesions and Carcinomas (17 papers). Yoshiya Horimoto collaborates with scholars based in Japan, United Kingdom and United States. Yoshiya Horimoto's co-authors include Mitsue Saito, Atsushi Arakawa, Akira Orimo, Urszula M. Polanska, Shinsaku Togo, Eric W.‐F. Lam, Emi Tokuda, Katsuya Nakai, Julie Millour and Rosa Aligué and has published in prestigious journals such as Nucleic Acids Research, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Yoshiya Horimoto

84 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoshiya Horimoto Japan 20 694 495 378 235 170 97 1.2k
Sharon B. Sams United States 17 514 0.7× 382 0.8× 229 0.6× 208 0.9× 134 0.8× 40 1.0k
Alexios Matikas Sweden 19 929 1.3× 395 0.8× 413 1.1× 370 1.6× 276 1.6× 92 1.4k
Jose Gerard Monzon Canada 17 773 1.1× 403 0.8× 214 0.6× 169 0.7× 175 1.0× 62 1.2k
Hao‐Xiang Wu China 22 596 0.9× 520 1.1× 393 1.0× 289 1.2× 251 1.5× 38 1.3k
Jeremy Force United States 19 616 0.9× 653 1.3× 588 1.6× 273 1.2× 163 1.0× 49 1.4k
Maria Martinez‐García Spain 18 675 1.0× 386 0.8× 318 0.8× 389 1.7× 189 1.1× 81 1.3k
David Páez Spain 20 828 1.2× 559 1.1× 265 0.7× 292 1.2× 146 0.9× 75 1.3k
Véronique Ouellet Canada 22 493 0.7× 770 1.6× 314 0.8× 205 0.9× 208 1.2× 47 1.4k
Marlies H.G. Langenberg Netherlands 15 749 1.1× 604 1.2× 367 1.0× 417 1.8× 108 0.6× 34 1.3k
Yi-Zhou Jiang China 23 648 0.9× 681 1.4× 827 2.2× 282 1.2× 94 0.6× 41 1.5k

Countries citing papers authored by Yoshiya Horimoto

Since Specialization
Citations

This map shows the geographic impact of Yoshiya Horimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshiya Horimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshiya Horimoto more than expected).

Fields of papers citing papers by Yoshiya Horimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshiya Horimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshiya Horimoto. The network helps show where Yoshiya Horimoto may publish in the future.

Co-authorship network of co-authors of Yoshiya Horimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshiya Horimoto. A scholar is included among the top collaborators of Yoshiya Horimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshiya Horimoto. Yoshiya Horimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Horimoto, Yoshiya, et al.. (2024). Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery. Japanese Journal of Clinical Oncology. 54(5). 556–561. 1 indexed citations
3.
Yanagihara, Hiromi, Yoshiya Horimoto, Tatsuhiko Imaoka, et al.. (2023). Azithromycin induces read-through of the nonsense Apc allele and prevents intestinal tumorigenesis in C3B6F1 Apc/+ mice. Biomedicine & Pharmacotherapy. 164. 114968–114968. 5 indexed citations
4.
Horimoto, Yoshiya, Hidetaka Eguchi, Katsuya Nakai, et al.. (2023). BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer. Breast Cancer Research and Treatment. 203(1). 49–55. 1 indexed citations
5.
Horimoto, Yoshiya, Kaori Denda‐Nagai, Haruhiko Fujihira, et al.. (2023). Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer. Scientific Reports. 13(1). 5281–5281. 5 indexed citations
6.
Horimoto, Yoshiya, et al.. (2022). Impact of Diabetes on Patient Outcomes in Breast Cancer Patients. Breast Care. 17(5). 480–485. 4 indexed citations
7.
Horimoto, Yoshiya, et al.. (2022). Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer. Breast Cancer Research and Treatment. 196(2). 291–298. 12 indexed citations
8.
Horimoto, Yoshiya, et al.. (2020). High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer. Breast Cancer Research and Treatment. 183(1). 41–48. 10 indexed citations
9.
Takahashi, Yuka, Yoshiya Horimoto, Kaoru Mogushi, et al.. (2020). Short somatic alterations at the site of copy number variation in breast cancer. Cancer Science. 112(1). 444–453. 7 indexed citations
10.
11.
Horimoto, Yoshiya, Masahiko Tanabe, Kaoru Mogushi, et al.. (2019). Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification. The American Journal of Surgical Pathology. 43(9). 1221–1228. 6 indexed citations
12.
Horimoto, Yoshiya, Masahiko Tanabe, Yuko Ichikawa, et al.. (2018). Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer. Medical Oncology. 35(4). 48–48. 7 indexed citations
13.
14.
Ogiya, Akiko, Rie Horii, Tadahiko Shien, et al.. (2016). Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer. 24(3). 473–482. 13 indexed citations
15.
Yamashita, Hiroko, Akiko Ogiya, Tadahiko Shien, et al.. (2015). Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 23(6). 830–843. 34 indexed citations
16.
Horimoto, Yoshiya, Atsushi Arakawa, Masahiko Tanabe, et al.. (2015). Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients. Journal of Clinical Pathology. 68(10). 825–829. 10 indexed citations
17.
Horimoto, Yoshiya, Atsushi Arakawa, Narumi Harada‐Shoji, et al.. (2014). Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases. British Journal of Cancer. 112(2). 345–351. 26 indexed citations
18.
Horimoto, Yoshiya, Atsushi Arakawa, Masahiko Tanabe, et al.. (2014). Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer. 14(1). 550–550. 22 indexed citations
19.
Millour, Julie, Natalia de Olano, Yoshiya Horimoto, et al.. (2011). ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance. Molecular Cancer Therapeutics. 10(6). 1046–1058. 132 indexed citations
20.
Horimoto, Yoshiya, et al.. (2007). A CASE OF PRIMARY COLON CANCER SHOWING MARKED EXTRAMURAL DEVELOPMENT. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 68(10). 2575–2579. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sharon B. Sams Breakdown of academic impact, for papers by Alexios Matikas Breakdown of academic impact, for papers by Jose Gerard Monzon Breakdown of academic impact, for papers by Hao‐Xiang Wu Breakdown of academic impact, for papers by Jeremy Force Breakdown of academic impact, for papers by Maria Martinez‐García Breakdown of academic impact, for papers by David Páez Breakdown of academic impact, for papers by Véronique Ouellet Breakdown of academic impact, for papers by Marlies H.G. Langenberg Breakdown of academic impact, for papers by Yi-Zhou Jiang
Rankless by CCL
2026